BioSpace News Archive

Investment will enable next-level growth of pioneering immersive therapy for depression, anxiety and other behavioral health conditions.

CareLight Solutions is proud to now be offering a complete line of industry-leading Light Therapy products to the public.

Mitchael Freeman, COO of Ocutrx Vision Technologies, LLC, a California-based technology startup developing a state-of-the-art augmented reality headset, this week delivered a forward-looking high-tech AR architecture presentation on the evolution of wearables in the healthcare space at the Medical Design & Manufacturing West Conference in Anaheim.

T3D Therapeutics, Inc. announced the formation of a new Scientific Advisory Board in concert with the initiation of the PIONEER Phase 2 clinical trial for its product candidate T3D-959 in patients with mild to moderate Alzheimer’s disease.

CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies, today announced that its biorepository in Rostock, Germany, which they believe holds the largest diversity of positive tested cases in the field of inherited rare diseases, has received accreditation from the College of American Pathologists (CAP).

Revance Therapeutics, Inc. (“Revance”) (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the pricing of $250.0 million aggregate principal amount of 1.75% convertible senior notes due 2027 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) in patients with metastatic triple-negative breast cancer (mTNBC) whose tumors expressed PD-L1 (Combined Positive Score [CPS] ≥10)

Today, Amgen Canada Inc. (“Amgen Canada”) announced Health Canada’s approval of the Marketing Authorization transfer of OTEZLA® (apremilast) from Celgene Corporation to Amgen Canada.

Newly developed recombinant antigens derived specifically from 2019-nCoV for use in infectious disease research, and assay and vaccine development

ChromaDex Corp. (NASDAQ:CDXC) today announced the launch of its flagship cellular health supplement Tru Niagen® (nicotinamide riboside) as a supplement offering in Nestlé Health Science’s (NHSc) personalized nutrition service – Persona Nutrition.